Vital Art and Science, LLC (VAS) Release: First FDA Cleared Ophthalmic App For Monitoring AMD And DR

New mVT™ Service accurately monitors progression of maculopathy

DALLAS--(BUSINESS WIRE)--Vital Art and Science, LLC (VAS), an emerging ophthalmic medical device company, has introduced the mVT™ Service, an innovative medical device and physician portal that conveniently and accurately tracks the progression of vision damaging diseases such as age related macular degeneration and diabetic retinopathy. The device is available only by prescription and consists of an easily downloaded app that can be used on any Apple smartphone or tablet. Patient test data are automatically uploaded to a Physician’s Portal where licensed eye-care professionals can monitor all patient test results.

“Our clinical trials have confirmed that the results from this convenient home test correlate well with in-office physician assessment and can potentially improve clinical outcomes by bringing in patients for earlier-than-planned examination and possibly treatment”

Age related macular degeneration is the leading cause of blindness for people over 60, and diabetic retinopathy vision loss continues to grow with the increasing prevalence of diabetes. The new mVT™ Service is the only simple, low cost, mobile, validated method available for these patients to test their vision at home. Patients take a simple 4-6 minute self-test, performed on the timetable recommended by the doctor (usually twice a week). The patient’s confidential results are automatically delivered to the Physician Portal for review and analysis.

The mVT™ Service utilizes proven patented proprietary algorithms to assess visual function and detect changes between physician visits. A significant change in the eye condition sends an alert to the doctor who will determine if an earlier intervention is required, such as new appointment, assessment or treatment.

“Our clinical trials have confirmed that the results from this convenient home test correlate well with in-office physician assessment and can potentially improve clinical outcomes by bringing in patients for earlier-than-planned examination and possibly treatment,” stated Mike Bartlett, company president. Studies have shown that catching and treating vision degradation early may prevent some vision loss. “Compliance with the prescribed mVT™ use is very high and patients feel more engaged in the management of their disease. Both patients and doctors appreciate the convenience,” Bartlett added. “Patients like to test at home and doctors like having the results automatically collected and available anytime for analysis,” he added.

The mVT™ Service, which includes the App and the Physician’s Portal, is available by prescription only and costs patients $8.95/month.

VAS is currently reviewing strategic partnerships and other opportunities with the mVT™ Service.

VAS is also welcoming a limited number of qualified prescribers into its early release program, the goal of which is to obtain prescriber/patient feedback and assure the mVT™ Service meets their needs.

Vital Art and Science, LLC, is advancing and commercializing innovative home diagnostics for treatable chronic diseases. VAS’s strategy has been to leverage the unique strengths of the Dallas/Fort Worth area universities and research facilities, as well as local electronic, telecommunications and health care companies. VAS is located at 17217 Waterview Pkwy, Richardson, TX 75252, 1-844-267-8019. For more information visit www.myvisiontrack.com.